Dr. Rosenthal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Medical Plaza Dr
Ste 180
Roseville, CA 95661Phone+1 916-781-1225Fax+1 916-797-4799
Summary
- Dr. Seth Rosenthal is a radiation oncologist in Roseville, CA and is affiliated with multiple hospitals in the area, including Marshall Medical Center, Mercy General Hospital, Mercy Hospital of Folsom, Mercy San Juan Medical Center, Sutter Auburn Faith Hospital, Sutter Davis Hospital, Sutter Medical Center, Sacramento, Sutter Roseville Medical Center, Mercy Medical Center Mount Shasta, and Sutter Roseville Medical Center. He received his medical degree from Yale School of Medicine and has been in practice 30 years. He specializes in urologic cancer and is experienced in prostate cancer. He has more than 100 publications and over 500 citings.
Education & Training
University of Pennsylvania Health SystemResidency, Radiation Oncology, 1988 - 1991
Yale-New Haven Medical CenterInternship, Internal Medicine, 1987 - 1988
Yale School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1991 - 2026
PA State Medical License 1988 - 2024- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012
Clinical Trials
- Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Jun 01
- Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Start of enrollment: 2005 Dec 01
Publications & Presentations
PubMed
- Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.Krishnan R Patel, Paul L Nguyen, James A Proudfoot, Yang Liu, Alan Dal Pra
European Urology Oncology. 2024-11-13 - Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Onc...Oliver Sartor, Theodore G Karrison, Howard M Sandler, Leonard G Gomella, Mahul Amin
European Urology. 2024-09-01 - Radiation Oncology Workforce: Supply and Demand.Arya Amini, Join Y Luh, Aaron Bush, Seth A Rosenthal
Journal of the American College of Radiology. 2024-07-01
Authored Content
- Perspectives from Council of Affiliated Regional Radiation Oncology SocietiesJune 2019
- Perspectives from Council of Affiliated Regional Radiation Oncology SocietiesJune 2019
Press Mentions
RTOG Foundation Establishes Four New Committees; Names Committee LeadersAugust 5th, 2022
Should Adjuvant Chemo Be Added to Treatment in Early High-Risk Prostate Cancer?April 8th, 2019
Modest Effects of Intense Therapy for Prostate CaMarch 19th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
